These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16469942)

  • 21. Nicotinic receptor function in schizophrenia.
    Leonard S; Adams C; Breese CR; Adler LE; Bickford P; Byerley W; Coon H; Griffith JM; Miller C; Myles-Worsley M; Nagamoto HT; Rollins Y; Stevens KE; Waldo M; Freedman R
    Schizophr Bull; 1996; 22(3):431-45. PubMed ID: 8873294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gating and habituation deficits in the schizophrenia disorders.
    Braff DL; Swerdlow NR; Geyer MA
    Clin Neurosci; 1995; 3(2):131-9. PubMed ID: 7583619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment.
    Oranje B; Aggernaes B; Rasmussen H; Ebdrup BH; Glenthøj BY
    Schizophr Bull; 2013 Mar; 39(2):472-80. PubMed ID: 22241164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Normalization of auditory sensory gating in schizophrenic patients after a brief period for sleep.
    Griffith JM; Waldo M; Adler LE; Freedman R
    Psychiatry Res; 1993 Oct; 49(1):29-39. PubMed ID: 8140180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients.
    Boutros NN; Brockhaus-Dumke A; Gjini K; Vedeniapin A; Elfakhani M; Burroughs S; Keshavan M
    Schizophr Res; 2009 Sep; 113(2-3):339-46. PubMed ID: 19524407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antipsychotic effects on auditory sensory gating in schizophrenia patients.
    Sánchez-Morla EM; Santos JL; Aparicio A; García-Jiménez MA; Villanueva C; Martínez-Vizcaíno V; Arango C
    Eur Neuropsychopharmacol; 2009 Dec; 19(12):905-9. PubMed ID: 19833483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker.
    Hashimoto K
    Curr Pharm Des; 2015; 21(26):3797-806. PubMed ID: 26044974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nicotinic modulation of auditory evoked potential electroencephalography in a rodent neurodevelopmental model of schizophrenia.
    Kohlhaas KL; Robb HM; Roderwald VA; Rueter LE
    Biochem Pharmacol; 2015 Oct; 97(4):482-487. PubMed ID: 26032639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
    Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
    Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association study of polymorphisms in the alpha 7 nicotinic acetylcholine receptor subunit and catechol-o-methyl transferase genes with sensory gating in first-episode schizophrenia.
    Liu X; Hong X; Chan RC; Kong F; Peng Z; Wan X; Wang C; Cheng L
    Psychiatry Res; 2013 Oct; 209(3):431-8. PubMed ID: 23598060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Independent domains of inhibitory gating in schizophrenia and the effect of stimulus interval.
    Hong LE; Summerfelt A; Wonodi I; Adami H; Buchanan RW; Thaker GK
    Am J Psychiatry; 2007 Jan; 164(1):61-5. PubMed ID: 17202545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P50 amplitude reduction: a nicotinic receptor-mediated deficit in first-degree relatives of schizophrenia patients.
    Turetsky BI; Dent G; Jaeger J; Zukin SR
    Psychopharmacology (Berl); 2012 May; 221(1):39-52. PubMed ID: 22048129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively.
    Riba J; Rodríguez-Fornells A; Barbanoj MJ
    Psychopharmacology (Berl); 2002 Dec; 165(1):18-28. PubMed ID: 12474114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
    Martin LF; Freedman R
    Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline dependency of nicotine's sensory gating actions: similarities and differences in low, medium and high P50 suppressors.
    Knott V; de la Salle S; Smith D; Phillipe T; Dort H; Choueiry J; Impey D
    J Psychopharmacol; 2013 Sep; 27(9):790-800. PubMed ID: 23744798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels.
    Csomor PA; Stadler RR; Feldon J; Yee BK; Geyer MA; Vollenweider FX
    Neuropsychopharmacology; 2008 Feb; 33(3):497-512. PubMed ID: 17460616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The -2 bp deletion in exon 6 of the 'alpha 7-like' nicotinic receptor subunit gene is a risk factor for the P50 sensory gating deficit.
    Raux G; Bonnet-Brilhault F; Louchart S; Houy E; Gantier R; Levillain D; Allio G; Haouzir S; Petit M; Martinez M; Frebourg T; Thibaut F; Campion D
    Mol Psychiatry; 2002; 7(9):1006-11. PubMed ID: 12399955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropsychological correlates of P50 sensory gating in patients with schizophrenia.
    Sánchez-Morla EM; Santos JL; Aparicio A; García-Jiménez MÁ; Soria C; Arango C
    Schizophr Res; 2013 Jan; 143(1):102-6. PubMed ID: 23148896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of Nicotine in Schizophrenia.
    Featherstone RE; Siegel SJ
    Int Rev Neurobiol; 2015; 124():23-78. PubMed ID: 26472525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis.
    Clementz BA; Geyer MA; Braff DL
    Biol Psychiatry; 1997 May; 41(10):1035-44. PubMed ID: 9129784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.